Does It Matter Whether Breast Cancer Recurs Early or Late?

Breast cancer’s late recurrence was examined in the most comprehensive study to date investigating its effect on mortality, evaluating factors that predict the disease course, and comparing survival after late recurrence with survival after early recurrence. Women who developed late recurrence were found to have a better prognosis than women who experienced early recurrence.
NOTE: Late recurrence is a term used for cancer recurrence occurring at least 10 years after diagnosis.
The report of this Danish study was published by Prof. Dr. Deirdre P. Cronin-Fenton and her team on 16 February 2022 in Journal of Clinical Oncology.
- Related topic: Which cancers RECUR, and at what rates?
The authors wrote that 72% to 83% of women with breast cancer in Scandinavian countries now survive for at least 10 years after primary diagnosis and treatment. However, little is known about their long-term prognosis. Previous data from this study group, among 20,315 women who had survived disease-free for 10 years, showed that the overall incidence of breast cancer recurrence from 10 to 32 years was 17%. The risk of late breast cancer recurrence was highest in women with estrogen receptor (ER)-positive tumors and lymph-node involvement.
Why Can Cancer Recur Late?
Late-recurring cancers are thought to arise from micrometastases (very small sites of cancer spread) or dormant cancer cells that reactivate and proliferate.
Low-risk cancers have lower reactivation rates than high-risk cancers. ER-positive and low-risk ER-negative cancers may have longer periods of dormancy. This less aggressive biological behavior is also likely to promote slower disease progression after breast cancer recurrence.
Few studies have investigated survival after late breast cancer recurrence. In particular, no studies have investigated the potential effect on mortality of factors predicting the disease course after breast cancer recurrence occurring 10 years after diagnosis.
The Danish researchers therefore conducted a population-based cohort study to investigate the effect of late breast cancer recurrence on breast cancer-specific and all-cause mortality. They evaluated potential prognostic (predictive of the disease course) factors, including characteristics of the primary tumor and the site and treatment of late recurrence. They also compared survival after late breast cancer recurrence with survival after early breast cancer recurrence.
Using the Danish Breast Cancer Group and other nationwide databases, the study team identified women who had early or late breast cancer recurrence during the period from 2004 to 2018 and were alive 6 months after recurrence. They followed these women until death from breast cancer, death from other causes, 10 years, or 31 December 2018, whichever came first. The team calculated mortality rates per 1000 person-years and cumulative breast cancer mortality rates for early and late recurrence, and according to the characteristics of the primary tumor and late recurrence.
Results
- Of 2,004 patients with late recurrence, 721 died from breast cancer, and median survival for these patients was 10 years; the mortality rate was 84.8 per 1,000 person-years, and the 10-year cumulative mortality rate was 50%.
- Among 1,528 patients with early recurrence, there were 1,092 breast cancer deaths, with a median survival of 4 years; the mortality rate was 173.9 per 1,000 person-years, and the 10-year cumulative mortality rate was 72%.
- The study team observed a 28% lower risk of breast cancer-specific mortality in patients who developed late recurrence compared with early recurrence (HR 0.72; 95% confidence interval 0.62 to 0.85).
- Factors identified as increasing the risk of death after late recurrence were advanced stage of the primary tumor, distant metastases, adjuvant treatment for regional recurrence, and systemic treatment for distant recurrence.
- Factors identified as reducing the risk of death after late recurrence were breast-conserving surgery at initial diagnosis, regional rather than distant metastatic recurrence, and late recurrence after recurrence surgery.
In conclusion, patients with late recurrence were found to have a more favorable prognosis than those with early recurrence. The site of recurrent disease, meaning whether recurrence was localized or widespread, was the main prognostic factor for breast cancer-related mortality. Because late breast cancer recurrence is less aggressive and associated with a better prognosis than early recurrence, this may provide some reassurance to patients who develop late breast cancer recurrence and may affect their quality of life after late recurrence. Future studies should aim to distinguish the biology of early and late recurrence.
Another point patients in this situation should remember is that around 2018, the year this study ended, drugs that made a very important contribution to the lives of patients with breast cancer became widely used: CDK 4/6-class cancer drugs. The effects of these drugs, which make a difference, could naturally not be measured during the study’s follow-up years.
The study was supported by grants from the Danish Cancer Society.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.